ALXO
ALX Oncology Holdings Inc. Common Stock
stockNASDAQ
alx oncology (previously alexo therapeutics) is a clinical-stage immuno-oncology company developing therapies that block the cd47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. our lead candidate, alx148, is a fusion protein that comprises an engineered high affinity cd47 binding domain of sirpa linked to an inactive fc region of human immunoglobulin. alx148 is currently being investigated in a phase 1 study in combination with checkpoint inhibitors and targeted anti-cancer antibodies (nct03013218). for more information about the company, please visit our website at www.alxoncology.com
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.18 | 2026-10-28 | +14.38% | -1.418 |
| 1M | 1.21 | 2026-10-05 | +11.54% | -0.669 |
| 3M | 1.97 | 2026-08-04 | -31.49% | -0.426 |
| 6M | 1.88 | 2026-05-04 | -28.21% | 0.565 |
| 1Y | 1.46 | 2025-11-04 | -7.55% | 0.446 |
| 2Y | 1.49 | 2024-11-04 | -9.42% | — |
| 5Y | 52.35 | 2021-11-04 | -97.42% | 1.327 |
ALX Oncology Holdings Inc. Common Stock (NASDAQ:ALXO) stock price today is $1.35, and today's volume is 247,527. ALXO is up 4.628% today. The 30 day average volume is 1.50M. ALXO market cap is $186.63M with 138.28M shares outstanding.